

Transparency Notification of Tolefi SA (Article 14 of the Law of 2 May 2007)

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of cell therapies, today announces it has received a transparency declaration from Tolefi SA in accordance with the Belgian Law of 2nd May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.

As of today, the Cardio3 Biosciences share capital amounts to EUR 27,438,380.63 and is represented by a total 7,847,187 shares (each share given one voting right).

Transparency notification from Tolefi SA

Cardio3 BioSciences received on 5 March 2015 a transparency notification from Tolefi SA having passed, on 3 March 2015, below the 30% threshold.

- Reason for notification: passive crossing of the threshold.
- Notification by a parent company or controlling person.
- Person holdings notification :

Name	Address
Tolefi SA	27, Drève de Carloo, 1180 Bruxelles
Serge Goblet	
Isabelle Thoumyre	

Voting rights	Previous notification	Post the transaction			
		# voting rights		% voting rights	
Holder of voting rights		Attached to shares	Non related securities	Attached to shares	Non related securities
TOLEFI SA	2,267,844	2,267,844	-	28.90%	-
Serge Goblet		-	-	-	-
Isabelle Thoumyre		-	-	-	-
TOTAL		2,267,844	-	28.90%	-

Tolefi SA is a family holding company 100% owned by Mr. Serge Goblet and his wife Isabelle Thoumyre. Tolefi SA also holds 2,504 warrants giving 2,504 voting rights.

*** END ***



PRESS RELEASE

REGULATED INFORMATION

5 MARCH 2015

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

For Europe: Consilium Strategic Communications

Amber Bielecka, Chris Welsh, Laura Thornton

For the U.S: The Ruth Group

Lee Roth (Investors), Kirsten Thomas (Media)

www.c3bs.com

Tel: +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 20 3709 5700

cardio3@consilium-comms.com

Tel: +1 646 536 7012 / 7014

lroth@theruthgroup.com

kthomas@theruthgroup.com

To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com.

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

About Cardio3 BioSciences

Cardio3 BioSciences is a leading clinical-stage biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA), and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure[®], an autologous stem cell therapeutic using adult guided stem cells for the condition of congestive heart failure. The Company's lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cath_{ez}[®]) and for cardiac surgery involving mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit www.c3bs.com.

Forward looking statements

C3BS-CQR-1, C-Cure, CM-CS1, C-Cath_{ez}, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath_{ez}, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure[®] and Phase I clinical trial for CM-CS1, additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.